SCHEMBL3873244

SCHEMBL3873244

Cc1c(Cl)cccc1S(=O)(=O)N(C)Cc1cccc(C(=O)NCC2CCCCC2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.51
ALDH1A1 P00352 3/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HDAC6 Q9UBN7 1/20 0.45
CXCR3 P49682 2/20 0.45
PKM P14618 1/20 0.45
POLB P06746 2/20 0.45
CACNA1H O95180 1/20 0.42
NPC1 O15118 1/20 0.41
CNR2 P34972 1/20 0.41
CA2 P00918 1/20 0.41
HSD11B1 P28845 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881153 0.87 ALDH1A1 (0.51) HTTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3872261 0.84 ALDH1A1 (0.56) HTTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3878752 0.80 CXCR3 (0.46) HTTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3872528 0.80 MMP13 (0.50) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL3883351 0.79 MRGPRX4 (0.52) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL3872830 0.79 ROCK2 (0.46) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL3878132 0.79 HTT (0.58) HTTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3882723 0.79 ALDH1A1 (0.51) HTTALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL3872847 0.78 TP53 (0.48) ALDH1A1SMN1; SMN2
SCHEMBL3874660 0.78 ROCK2 (0.49) ALDH1A1LMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 HTT 4278/4885ALDH1A1 210/4885LMNA 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.